Skip to main content Deutsch

Szakacs Lab

Gergely Szakacs, Univ.-Prof., PhD

Research Focus

Therapy resistance in cancer

Elucidating the molecular basis of therapy resistance in cancer is an unmet clinical need.

Our aim is to characterize the evolution of cancer therapy resistance. Based on preliminary results we hypothesize that therapy resistance is linked to the rare population DTP cells that survive treatment through the stabilization of transient drug-induced phenotypes, until mechanisms ensuring stable drug resistance emerge. Our aim is to characterize tumors during different stages of therapy to identify vulnerabilities of this adaptive process.

Effective targeting of DTPs will result in a paradigm shift, changing the focus from countering drug resistance mechanisms to preventing or delaying therapy resistance, leading to improved treatments of patients.

In 2020, we established a research consortium within the university, and successfully applied for funding from the FWF Doc-fund to establish an excellence-based graduate training program.

Selected Publications

Unshielding Multidrug Resistant Cancer through Selective Iron Depletion of P-Glycoprotein-Expressing Cells
Cserepes M, Türk D, Tóth S, Pape VFS, Gaál A, Gera M, Szabó JE, Kucsma N, Várady G, Vér-tessy BG, Streli C, Szabó PT, Tovari J, Szoboszlai N, Szakács G.
Cancer Res. 2020 Feb 15;80(4):663-674. doi: 10.1158/0008-5472.CAN-19-1407.

Celecoxib Prevents Doxorubicin-Induced Multidrug Resistance in Canine and Mouse Lymphoma Cell Lines
Karai E, Szebényi K, Windt T, Fehér S, Szendi E, Dékay V, Vajdovich P, Szakács G, Füredi A.
Cancers (Basel). 2020 Apr 29;12(5). doi: 10.3390/cancers12051117.

Establishment and Characterization of a Brca1-/-, p53-/- Mouse Mammary Tumor Cell Line
Hámori L, Kudlik G, Szebényi K, Kucsma N, Szeder B, Póti Á, Uher F, Várady G, Szüts D, Tóvári J, Füredi A, Szakács G.
Int J Mol Sci. 2020 Feb 11;21(4). doi: 10.3390/ijms21041185.

In vivo characterization of [18F]AVT-011 as a radio-tracer for PET imaging of multidrug resistance
Kannan P, Füredi A, Dizdarevic S, Wanek T, Mairinger S, Collins J, Falls T, van Dam RM, Ma-heshwari D, Lee JT, Szakács G, Langer O.
Eur J Nucl Med Mol Imaging. 2019 Nov 15;. doi: 10.1007/s00259-019-04589-w.

Pegylated liposomal formulation of doxorubicin overcomes drug resistance in a genetically engineered mouse model of breast cancer
Füredi A, Szebényi K, Tóth S, Cserepes M, Hámori L, Nagy V, Karai E, Vajdovich P, Imre T, Szabó P, Szüts D, Tóvári J, Szakács G.
J Control Release. 2017 Sep 10;261:287-296. doi: 10.1016/j.jconrel.2017.07.010.

Identification and Validation of Compounds Selectively Killing Resistant Cancer: Delineating Cell Line-Specific Effects from P-Glycoprotein-Induced Toxicity
Füredi A, Tóth S, Szebényi K, Pape VF, Türk D, Kucsma N, Cervenak L, Tóvári J, Szakács G.
Mol Cancer Ther. 2017 Jan;16(1):45-56. doi: 10.1158/1535-7163.MCT-16-0333-T.

Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance
Szakács G, Hall MD, Gottesman MM, Boumendjel A, Kachadourian R, Day BJ, Baubichon-Cortay H, Di Pietro A.
Chem Rev. 2014 Jun 11;114(11):5753-74. doi: 10.1021/cr4006236.

Identification of compounds selectively killing multidrug-resistant cancer cells
Türk D, Hall MD, Chu BF, Ludwig JA, Fales HM, Gottesman MM, Szakács G.
Cancer Res. 2009 Nov 1;69(21):8293-301. doi: 10.1158/0008-5472.CAN-09-2422.

Targeting multidrug resistance in cancer
Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM.
Nat Rev Drug Discov. 2006 Mar;5(3):219-34. doi: 10.1038/nrd1984.

Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells
Szakács G, Annereau JP, Lababidi S, Shankavaram U, Arciello A, Bussey KJ, Reinhold W, Guo Y, Kruh GD, Reimers M, Weinstein JN, Gottesman MM.
Cancer Cell. 2004 Aug;6(2):129-37. doi: 10.1016/j.ccr.2004.06.026.

All Publications


Presentation Gergely Szakacs, Agnes Csiszar


Financial Support

  • EU/Horizont 2020
  • Fonds des Bürgermeisters der Bundeshauptstadt Wien (Agnes Csiszar)
  • FWF Der Wissenschaftsfonds: Dok 59
  • DOC-Stipendium der Österreichischen Akademie der Wissenschaften (Silvia Steinbauer)